JP2025508746A5 - - Google Patents

Info

Publication number
JP2025508746A5
JP2025508746A5 JP2024548633A JP2024548633A JP2025508746A5 JP 2025508746 A5 JP2025508746 A5 JP 2025508746A5 JP 2024548633 A JP2024548633 A JP 2024548633A JP 2024548633 A JP2024548633 A JP 2024548633A JP 2025508746 A5 JP2025508746 A5 JP 2025508746A5
Authority
JP
Japan
Prior art keywords
characteristic peaks
exhibits
crystal morphology
group
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024548633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508746A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/012898 external-priority patent/WO2023158607A1/en
Publication of JP2025508746A publication Critical patent/JP2025508746A/ja
Publication of JP2025508746A5 publication Critical patent/JP2025508746A5/ja
Pending legal-status Critical Current

Links

JP2024548633A 2022-02-18 2023-02-13 化合物の多形形態及び多形形態を生成する方法 Pending JP2025508746A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263311869P 2022-02-18 2022-02-18
US63/311,869 2022-02-18
PCT/US2023/012898 WO2023158607A1 (en) 2022-02-18 2023-02-13 Polymorphic forms and methods of producing polymorphic forms of a compound

Publications (2)

Publication Number Publication Date
JP2025508746A JP2025508746A (ja) 2025-04-10
JP2025508746A5 true JP2025508746A5 (cg-RX-API-DMAC10.html) 2026-02-24

Family

ID=87578977

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024548633A Pending JP2025508746A (ja) 2022-02-18 2023-02-13 化合物の多形形態及び多形形態を生成する方法

Country Status (9)

Country Link
US (1) US20250034183A1 (cg-RX-API-DMAC10.html)
EP (1) EP4479409A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025508746A (cg-RX-API-DMAC10.html)
KR (1) KR20240152889A (cg-RX-API-DMAC10.html)
CN (1) CN119053613A (cg-RX-API-DMAC10.html)
AU (1) AU2023221889A1 (cg-RX-API-DMAC10.html)
CA (1) CA3252569A1 (cg-RX-API-DMAC10.html)
MX (1) MX2024010008A (cg-RX-API-DMAC10.html)
WO (1) WO2023158607A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
EP4775207A2 (en) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EP4161925A4 (en) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
AU2006249347A1 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
EP4775207A2 (en) * 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis

Similar Documents

Publication Publication Date Title
JP2023504643A5 (cg-RX-API-DMAC10.html)
JP2024520677A5 (cg-RX-API-DMAC10.html)
JP2023537285A5 (cg-RX-API-DMAC10.html)
JP2023002662A5 (cg-RX-API-DMAC10.html)
JP2023504644A5 (cg-RX-API-DMAC10.html)
JP2015522616A5 (cg-RX-API-DMAC10.html)
JP2023504646A5 (cg-RX-API-DMAC10.html)
RU2017114109A (ru) Кристаллические модификации элобиксибата
JP2023546125A5 (cg-RX-API-DMAC10.html)
JP2024516371A5 (cg-RX-API-DMAC10.html)
JP2023504647A5 (cg-RX-API-DMAC10.html)
JP2018518537A5 (cg-RX-API-DMAC10.html)
RU2015150039A (ru) Кристаллическая модификация
HRP20240265T1 (hr) Spoj izoksazola kao fxr agonist i farmaceutski pripravci koji ga sadrže
JP2023519891A5 (cg-RX-API-DMAC10.html)
TW200829259A (en) Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
WO2016131414A1 (zh) 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
JP2013526482A (ja) カナグリフロジン含有錠剤
JP2017537061A5 (cg-RX-API-DMAC10.html)
JP5698682B2 (ja) トライアシル−3−ヒドロキシフェニルアデノシン及びその血中脂肪の調節用途
JP2011527332A5 (cg-RX-API-DMAC10.html)
IL297844A (en) Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
JP2024541569A5 (cg-RX-API-DMAC10.html)
JP2018529779A5 (cg-RX-API-DMAC10.html)
JP2015508068A5 (cg-RX-API-DMAC10.html)